PT - JOURNAL ARTICLE AU - Ata Ur Rehman Maaz AU - Jim O'Doherty AU - Mehdi Djekidel TI - <sup>68</sup>Ga-DOTATATE PET/CT for Neuroblastoma staging. Utility for clinical use AID - 10.2967/jnmt.120.258939 DP - 2021 Apr 01 TA - Journal of Nuclear Medicine Technology PG - jnmt.120.258939 4099 - http://tech.snmjournals.org/content/early/2021/04/02/jnmt.120.258939.short 4100 - http://tech.snmjournals.org/content/early/2021/04/02/jnmt.120.258939.full AB - MIBG imaging has been the standard for neuroblastoma staging for many decades. Novel agents such as 18F DOPA and 68Ga DOTATATE are being used nowadays in academic centers. During the COVID-19 pandemic, procurement of MIBG has proved particularly challenging, necessitating the use of 68Ga DOTATATE positron emission tomography. Methods: 68Ga DOTATATE PET/CT imaging was carried out for staging of three pediatric patients with Neuroblastoma at our institution. A review of the literature was also completed. Results: 68Ga-DOTATATE is FDA approved for imaging of somatostatin receptor (SSTR) positive gastroenteropancreatic neuroendocrine tumors. 68Ga DOTATATE PET/CT scans were successfully carried out in all patients. All patients showed DOTATATE avid disease. PET scans showed excellent spatial resolution and demonstrated high accuracy in concordance with current EANM guidelines. Conclusion: We have presented 68Ga-DOTATATE PET/CT imaging believe it can be reliably used as an alternative to MIBG for staging of neuroblastoma. Its advantages include technical, clinical and practical advantages making it an attractive option. Further multicenter studies are required before it can be recommended for standard clinical use.